Advertisement
Advertisement
U.S. markets open in 6 hours 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Nanobiotix S.A. (NBTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.7100+0.0300 (+0.82%)
At close: 12:56PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

    PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursda

  • GlobeNewswire

    NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

    Data show that radiotherapy-activated NBTXR3 was feasible and well tolerated in the complete dose escalation part of a Study 2019-1001, a phase 1 evaluation of NBTXR3 for patients with locally advanced pancreatic adenocarcinomaThe recommended phase 2 dose for radiotherapy-activated NBTXR3 in pancreatic cancer was established at 42% of gross tumor volume and the dose expansion part of the study is ongoing in the United StatesThe company expects to report safety and early efficacy data from the es

  • Benzinga

    Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients

    Nanobiotix (NASDAQ: NBTX) announced updated data from phase 1 Study 1100 of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy. Reported data included 28 patients, with 21 evaluable for early signs of efficacy. Treatment remained feasible and well-tolerated. Objective reduction from baseline in target lesions was observed in 71.43% of evaluable patients (15/21). 42.86% of evaluab

Advertisement
Advertisement